论文部分内容阅读
目的对比观察TEC与FEC方案在局部晚期乳腺癌新辅助化疗中的疗效。方法将118例晚期乳腺癌患者随机分为TEC方案组和FEC方案组,每组59例。观察两组的疗效及不良反应。结果 118例患者均接受了4个周期的TEC方案或FEC方案的化疗,TEC方案的总有效率为76.3%,FEC方案的总有效率为64.4%,两组比较差异有统计学意义(P﹤0.05)。两组常见的不良反应为恶心呕吐,脱发,白细胞降低,血小板降低等,TEC方案组的不良反应发生率高于FEC方案组。结论对晚期乳腺癌进行新辅助化疗,TEC方案疗效优于FEC方案,但不良反应较大。临床应根据不同情况选择合理的化疗方案。
Objective To compare the efficacy of TEC and FEC regimen in neoadjuvant chemotherapy for locally advanced breast cancer. Methods 118 patients with advanced breast cancer were randomly divided into TEC group and FEC group, 59 cases in each group. The curative effect and adverse reaction of the two groups were observed. Results All 118 patients underwent 4 cycles of chemotherapy with TEC or FEC. The total effective rate of TEC was 76.3% and the total effective rate of FEC was 64.4%, with significant difference between the two groups (P < 0.05). The two groups of common adverse reactions are nausea and vomiting, hair loss, leukopenia, thrombocytopenia, etc., TEC regimen group adverse reaction rate was higher than the FEC regimen group. Conclusions Neoadjuvant chemotherapy for advanced breast cancer, TEC program curative effect is better than the FEC program, but adverse reactions. According to different clinical conditions should choose a reasonable chemotherapy.